Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4 Pite > 98.0% (HPLC) Lenvatinib Mesylate Faktori Entèmedyè
Ruifu Chimik Pwovizyon pou Lenvatinib Mesylate Entèmedyè ak Pite segondè
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Non Chimik | Methyl 4-chloro-7-methoxyquinoline-6-carboxylate |
Sinonim | Lenvatinib enpurte 47;4-Chloro-7-Methoxyquinoline-6-Carboxylic Asid Methyl Ester;4-Chloro-7-Methoxy-6-Quinolinecarboxylic Asid Methyl Ester;Lenvaint-D |
Nimewo CAS | 205448-66-4 |
Nimewo CAT | RF-PI1970 |
Estati Stock | Nan Stock, Pwodiksyon Echèl Jiska Tòn |
Fòmil molekilè | C12H10ClNO3 |
Pwa molekilè | 251.67 |
Pwen bouyi | 377.4±37.0℃ |
Dansite | 1.320±0.06 g/cm3 |
Mak | Ruifu Chimik |
Atik | Espesifikasyon |
Aparans | Off-blan pou jòn Solid poud |
Spectre 1H RMN | Ki konsistan avèk estrikti |
Pite / Metòd analiz | >98.0% (HPLC) |
Pèt sou siye | <1.00% |
Enpurte total | <2.00% |
Tès Creole | Enterprise Standard |
Itilizasyon | Entèmedyè / Enpurte nan Lenvatinib Mesylate (CAS: 857890-39-2) |
Pake: Boutèy, sak papye aliminyòm, 25kg / tanbou katon, oswa selon kondisyon kliyan an
Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè ak imidite
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate (CAS: 205448-66-4) se yon entèmedyè nan Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib se yon dwòg kansè tiwoyid devlope pa Eisai Corporation nan Japon (Kòd: E7080), ki fè pati inibitè a nan oral milti-reseptè tirozin kinaz (RTK) epi li ka anpeche aktivite a kinaz nan vaskilè endothelial kwasans faktè Reseptè R1 (FLT1), VEG-FR2 (KDR), R3 (FLT4).Lenvatinib kapab tou anpeche patisipasyon lòt RTK nan anjyogenesis patolojik, kwasans timè, ak pwogresyon kansè eksepte pou fonksyon selilè nòmal yo ki gen ladan reseptè FGFR1, 2, 3, ak 4 fibroblast kwasans faktè (FGF);reseptè faktè kwasans ki sòti nan plakèt (PDGFR [alfa]), KIT, ak RET.[Endikasyon]: Lenvatinib se apwopriye pou tretman pasyan kansè tiwoyid nan repetisyon lokal oswa kalite metastaz, kalite pwogresivite ak yòd radyoaktif-refractory kalite différenciés.